US-based biotech Diapin Therapeutics has announced groundbreaking results from the latest preclinical tests for its novel oral tripeptide compound, DT-109, which has demonstrated the ability to inhibit the progression of non-alcoholic steatohepatitis (NASH) in monkeys. The study, now published in Cell Metabolism, was conducted by Diapin’s founder Dr. Eugene Chen and researchers at Xi’an Jiaotong University and the University of Michigan.
DT-109’s Impact on Liver Fat and Fibrosis
According to Diapin, the study showed that treatment with DT-109 led to a significant reduction in liver fat, attenuation of fibrosis, and improvement in the Non-Alcoholic Fatty Liver Disease Activity Score (NAS), a critical clinical endpoint in NASH clinical trials. These findings position DT-109 as a promising candidate for further development. The compound is now being prepared to enter clinical trials in 2024.
Mechanism of Action and Broad Potential Applications
DT-109 is a three amino acid peptide that is believed to act on several pathways, including increasing fatty acid oxidation, decreasing free radicals, and reducing inflammation. These effects are achieved by modulation of the intestinal microbiome and regulation of bacterially produced molecules. Beyond its potential in targeting NASH, DT-109 is also viewed as having potential against various lipid-mediated medical conditions.
Diapin’s Origins and Global Partnership
Diapin was established by Dr. Chen as a spin-out from the University of Michigan. Among the firm’s earliest investors is China-based Beijing SL Pharmaceuticals Ltd, which will be a strategic partner for the global development of DT-109.-Fineline Info & Tech
